We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+11.22%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.1B
AUM Growth
-$126M
Cap. Flow
-$161M
Cap. Flow %
-14.63%
Top 10 Hldgs %
85.29%
Holding
45
New
1
Increased
9
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$11.5M
2
RLAY icon
Relay Therapeutics
RLAY
+$6.84M
3
LLY icon
Eli Lilly
LLY
+$6.61M
4
ILMN icon
Illumina
ILMN
+$4.06M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.81M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$31.1M
2
BPMC
Blueprint Medicines
BPMC
+$28.9M
3
BLFS icon
BioLife Solutions
BLFS
+$22.5M
4
EXAS
Exact Sciences
EXAS
+$16M
5
NTLA icon
Intellia Therapeutics
NTLA
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGS icon
1
GeneDx Holdings
WGS
$1.98B
$324M 29.48%
3,507,164
– –
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$166M 15.12%
7,707,165
-1,000,000
-11% -$22.5M
RVMD icon
3
Revolution Medicines
RVMD
$38.8B
$106M 9.68%
2,887,933
-810,000
-22% -$31.1M
LAB icon
4
Standard BioTools
LAB
$343M
$91.3M 8.31%
76,075,636
– –
ILMN icon
5
Illumina
ILMN
$30.3B
$61.5M 5.6%
645,000
+50,000
+8% +$4.06M
RNAM
6
DELISTED
Avidity Biosciences
RNAM
$50.4M 4.59%
1,775,000
-270,000
-13% -$8.05M
VERV
7
DELISTED
Verve Therapeutics
VERV
$46M 4.19%
4,095,571
+100,000
+3% +$570K
RLAY icon
8
Relay Therapeutics
RLAY
$4.04B
$39.4M 3.59%
11,398,574
+2,300,000
+25% +$6.84M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$29.1B
$26.6M 2.42%
81,500
-38,500
-32% -$10.7M
GPCR icon
10
Structure Therapeutics
GPCR
$3.39B
$25.4M 2.31%
1,225,000
+525,000
+75% +$11.5M
BEAM icon
11
Beam Therapeutics
BEAM
$2.66B
$24.7M 2.25%
1,450,000
+24,438
+2% +$426K
NGNE icon
12
Neurogene
NGNE
$657M
$19.4M 1.76%
1,295,361
– –
CDXS icon
13
Codexis
CDXS
$158M
$17.6M 1.6%
7,200,000
-900,000
-11% -$2.11M
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.63B
$16.9M 1.54%
990,097
+89,314
+10% +$3.81M
DNLI icon
15
Denali Therapeutics
DNLI
$3.67B
$12.5M 1.13%
890,000
-100,000
-10% -$1.41M
HIMS icon
16
Hims & Hers Health
HIMS
$7.13B
$11.5M 1.04%
230,000
+30,000
+15% +$1.36M
MAZE
17
Maze Therapeutics
MAZE
$1.49B
$9.31M 0.85%
758,857
-187,500
-20% -$1.95M
VCYT icon
18
Veracyte
VCYT
$3.59B
$7.47M 0.68%
276,308
– –
LLY icon
19
Eli Lilly
LLY
$996B
$6.63M 0.6%
+8,500
New +$6.61M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.69B
$6.08M 0.55%
650,000
+15,000
+2% +$165K
SEPN
21
Septerna Inc
SEPN
$1.57B
$5.85M 0.53%
553,268
– –
GH icon
22
Guardant Health
GH
$21.7B
$5.2M 0.47%
100,000
-150,000
-60% -$6.7M
EXAS
23
DELISTED
Exact Sciences
EXAS
$4.78M 0.44%
90,000
-315,000
-78% -$16M
PRME icon
24
Prime Medicine
PRME
$515M
$3.87M 0.35%
1,567,175
+1,200,000
+327% +$1.85M
AGIO icon
25
Agios Pharmaceuticals
AGIO
$1.84B
$3.33M 0.3%
100,000
-150,000
-60% -$4.55M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Casdin Capital held 45 positions worth $1.1B, down 10% from $1.22B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Casdin Capital withdrew a net $161M in Q2 2025, closing 12 positions and reducing 12 holdings. Its most notable exit was Blueprint Medicines, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Casdin Capital opened a new position in Eli Lilly worth $6.63M.

  • Casdin Capital's largest Q2 2025 buy was Eli Lilly: 8,500 shares worth $6.63M.
  • Casdin Capital added most to Structure Therapeutics in Q2 2025, an estimated $11.5M increase.
  • Casdin Capital's biggest Q2 2025 reduction was Revolution Medicines, cutting an estimated $31.1M.
  • Casdin Capital fully exited Blueprint Medicines in Q2 2025, selling an estimated $28.9M.
  • Casdin Capital's ten largest holdings make up 85% of its $1.1B portfolio in Q2 2025.
  • Casdin Capital opened 1 new position and closed 12 in Q2 2025.
  • Casdin Capital's portfolio value fell 10% quarter-over-quarter to $1.1B.

Based on Casdin Capital's 13F filing for Q2 2025, filed 14 Aug 2025.